Thermo Fisher Scientific’s Investment in Ionpath

Goodwin Procter advised Ionpath, Inc. on the deal.

Thermo Fisher Scientific announced its strategic investment in Ionpath, Inc.

Ionpath, Inc., based in Menlo Park, California, is a pioneer in high-definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate medical discovery and improve human health. With its MIBI technology and the expertise of world-class pathology and data science teams, Ionpath provides actionable insights to translational and clinical researchers at leading pharmaceutical, biotechnology, and research organizations in immuno-oncology, immunology, neuroscience, and infectious disease research.

Thermo Fisher Scientific (NYSE: TMO), headquartered in Waltham, Massachusetts, is a global provider of medical equipment, analytical instruments, reagents and consumables, software and services to tackle complex analytical challenges in research, diagnostics and clinical laboratories, with annual revenue of approximately $40 billion. 

The Goodwin team was led by Richard Hoffman (Picture), Adam Small, Shoaib Ghias and Steve Argentieri.

Involved fees earner: Steven Argentieri – Goodwin Procter; Shoaib Ghias – Goodwin Procter; Richard Hoffman – Goodwin Procter; Adam Small – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Ionpath, Inc.;

Martina Bellini

Author: Martina Bellini